Retrospective analysis of multi-institutional, patient-specific treatment planning results of high-dose-rate intracavitary brachytherapy for gynecological cancer using V100%
- 17 Downloads
The objective of this study was to clarify the usefuleness of the K parameters of the independent verification method using V100% (the volume of water receiving 100% of the prescription dose) for institutions implementing the high-dose-rate (HDR) intracavitary brachytherapy for gynecological cancer. The data of 249 plans of 11 institutions in Japan were used, and the constant K value obtained by a parameter fit for single-192Ir, two-192Ir, and three-192Ir systems was calculated. The predicted total dwell time calculated using the constant K value was defined as Tpr, and the total dwell time calculated using a radiation treatment planning system was defined as TRTP. The ratio of Tpr and TRTP for each plan was calculated. The constant K values (95% CI) obtained for each system outlined above were 1233 (1227–1240), 1205 (1199–1211), and 1171 (1167–1175), respectively. Regarding the Tpr/TRTP, the entire data were within 0.9–1.1. For accurate verification, it was clarified that constant K values should be calculated for each system. The Nuclear Regulatory Commission considers a difference of 20% between the prescribed total dose and the administered total dose as a reportable medical event. There is a need for a quick method to verify the accuracy with a minimum of 10% threshold of a plan. The constant K values in this study were obtained from multiple institutions, and the variation in the values among these institutions was small. The data obtained by this study may be used as a parameter of this verification method employed by numerous institutions, particularly those who have recently initiated HDR brachytherapy. In addition, for institutions already using this method, this data might be useful for the validation of the parameters which were used in such institutions.
KeywordsHigh-dose-rate brachytherapy Multi-institutional study Gynecological cancer Independent verification method Quality assurance
The authors sincerely thank the following institutions for providing sample data: Cancer Institute Hospital, Chiba Cancer Center, Gunma University Hospital, Kyorin University Hospital, Saitama prefectural Cancer Center, Showa University Hospital, Tokyo Medical University Hospital and Yokohama City University Medical Center.
This study was funded by a Kanto-Branch Research Grant from the Japanese Society of Radiological Technology.
Compliance with ethical standards
Conflict of interest
All authors declare that we have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 2.U.S. Nuclear Regulatory Commission (2003) Medical use of by-product material. Title 10, Chap. 1, Code of Federal Regulations d Energy. Part 35. Government Printing Office, Washington, DCGoogle Scholar
- 5.Thomadosen BR, Shahabi S, Stitt JA et al (1992) High dose rate intracavitary brachytherapy for carcinoma of the cervix: the Independent patient-specific treatment planning verification method using a benchmark plan 943 Madison system: II. Procedural and physical considerations. Int J Radiat Oncol Biol Phys 24:349–357CrossRefGoogle Scholar
- 13.Bidmead M, Briot E, Burger J et al (2004) Quality assurance of brachytherapy treatment planning system. In: Venselaar J, Calatayud JP (eds) A practical guide to quality control of brachytherapy equipment. ESTRO, Brussels, pp 215–231Google Scholar
- 16.Das RK, Thomadsen BR (2005) High dose rate sources and delivery system. In: Thomadsen BR et al (eds) Brachytherapy physics. Medical Physics Publishing Co., Madison, pp 59–74Google Scholar